Literature DB >> 34455705

Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency.

Taumoha Ghosh1,2,3, Angela Guerrero-Pena1,2, Madhuri Kashyap1,2, Ali G Saad1,4, Chad M Thorson1,5, Asha B Pillai1,2,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34455705      PMCID： PMC8629840          DOI： 10.1002/pbc.29314

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  22 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Cancer; a biological approach. I. The processes of control.

Authors:  M BURNET
Journal:  Br Med J       Date:  1957-04-06

3.  Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.

Authors:  J Sumegi; D Huang; A Lanyi; J D Davis; T A Seemayer; A Maeda; G Klein; M Seri; H Wakiguchi; D T Purtilo; T G Gross
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

4.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Authors:  Liping Song; Tasnim Ara; Hong-Wei Wu; Chan-Wook Woo; C Patrick Reynolds; Robert C Seeger; Yves A DeClerck; Carol J Thiele; Richard Sposto; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 5.  X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.

Authors:  Hamid Bassiri; W C Janice Yeo; Jennifer Rothman; Gary A Koretzky; Kim E Nichols
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

Authors:  Shahab Asgharzadeh; Jill A Salo; Lingyun Ji; André Oberthuer; Matthias Fischer; Frank Berthold; Michael Hadjidaniel; Cathy Wei-Yao Liu; Leonid S Metelitsa; Roger Pique-Regi; Peter Wakamatsu; Judith G Villablanca; Susan G Kreissman; Katherine K Matthay; Hiroyuki Shimada; Wendy B London; Richard Sposto; Robert C Seeger
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

7.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

Authors:  Liping Song; Shahab Asgharzadeh; Jill Salo; Kelly Engell; Hong-wei Wu; Richard Sposto; Tasnim Ara; Ayaka M Silverman; Yves A DeClerck; Robert C Seeger; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 8.  The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.

Authors:  Daniëlle Krijgsman; Marianne Hokland; Peter J K Kuppen
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

Review 9.  X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.

Authors:  Neelam Panchal; Claire Booth; Jennifer L Cannons; Pamela L Schwartzberg
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 10.  Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.

Authors:  Cristina Bottino; Alessandra Dondero; Francesca Bellora; Lorenzo Moretta; Franco Locatelli; Vito Pistoia; Alessandro Moretta; Roberta Castriconi
Journal:  Front Immunol       Date:  2014-02-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.